- 10 June
-
The Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, a collective member of the Ural Biomedical Cluster, has participated in the CHEMTECH URAL, first specialised forum and exhibition, held from May 26 to 28 in the Ekaterinburg-EXPO International Exhibition Centre. The organization acted as an industry partner for the event, bringing together key players from the pharmaceutical and chemical sectors of the region at its joint booth.
- 10 June
-
Pharmaceutical Chemistry: Towards Full-Cycle Production round table discussion was held as part of the business program at ChemTech Ural 2026. Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, was the keynote speaker at the event.
- 10 June
-
Medsintez Plant, one of Russia's leading manufacturers of insulins and drugs for the therapy of socially significant diseases, traditionally participated in the 11th (32nd) National Congress of Endocrinologists with International Participation. The event, themed Personalized Medicine in Endocrinology: From Fundamental Science to Clinical Practice, took place from 26 to 29 May in Moscow.
- 10 June
-
In 2025, the Governor of the Sverdlovsk Region, Denis Vladimirovich Pasler, signed a decree awarding the Regional Head's Certificate of Honour to Alexey Borisovich Podkorytov, CEO of Medsintez Plant LLC.
- Home
- Cluster members
- Ural Biomedical Company LLC
Ural Biomedical Company LLC
Genetic and gene and cell technologies (GCT), which make it possible to modify the properties of cells in a targeted manner, is a direction that the UN has officially recognized as a technology of the 21st century.
Hopes for the treatment of the most severe and massive diseases, such as cardiovascular, oncological and metabolic diseases, are associated with success in the development of GCT.
The small innovative enterprise Ural Biomedical Company LLC acts as a coordinator in this area, bringing together the efforts of specialists from the Department of Molecular and Cellular Technologies of the Ural State Medical University and the Laboratory of Cell and Gene Therapy Technology of the Institute of Medical Cellular Technologies in conducting an R&D cycle and implementing innovative projects for the development, production and use of a new generation of personalized medicines based on gene and gene-cell technologies based on the patented developments of one of the leading scientific schools in Russia – Professor O. G. Makeev's School.
Currently, the studies coordinated by Ural Biomedical Company LLC are at different stages of preclinical and clinical trials, which are highly recognized both in Russia and abroad – in particular, representatives of the above scientific school have obtained dozens of patents, have been awarded gold medals at European and Russian forums and exhibitions of biomedical technologies.
According to the National Society of Regenerative Medicine, a unique product for the Russian and world markets – AversGel – a gel for natural skin rejuvenation based on components of a certified human stem cell line, entered the top 10 breakthrough technologies in Russia in 2017 with the comment: "These technologies will remain with us for a long time. They will change the economy and politics, make a breakthrough in medicine, leave a cultural mark. Some of them are just taking shape, while others can take more than a decade to develop. But you need to know about them right now.”
